surufatinib   Click here for help

GtoPdb Ligand ID: 9769

Synonyms: HMPL-012 | HMPL012 | KDR-IN-1 | Sulanda® | VEGFR2 inhibitor [WO2011060746]
Approved drug
surufatinib is an approved drug (China (2020))
Compound class: Synthetic organic
Comment: Surufatinib is an oral tyrosine kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, to inhibit key angiogenic and immune pathways in solid tumours. Surufatinib's chemical structure is claimed in patent WO2011060746, and its use as a potential anti-angiogenic agent is included [1]. In this patent it is referred to as 'Compound of Formula A'.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 120.62
Molecular weight 480.19
XLogP 2.96
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(CCNS(=O)(=O)Cc1cccc(c1)Nc1nccc(n1)Oc1ccc2c(c1)cc([nH]2)C)C
Isomeric SMILES CN(CCNS(=O)(=O)Cc1cccc(c1)Nc1nccc(n1)Oc1ccc2c(c1)cc([nH]2)C)C
InChI InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
InChI Key TTZSNFLLYPYKIL-UHFFFAOYSA-N
Bioactivity Comments
This compound inhbits the hERG channel with an IC50of 6.8 μM [1].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
kinase insert domain receptor Hs Inhibitor Inhibition 7.7 pIC50 - 1
pIC50 7.7 (IC50 2.1x10-8 M) [1]
Description: In a biochemical assay using recombinant KDR kinase catalytic domain.
fibroblast growth factor receptor 1 Hs Inhibitor Inhibition 7.3 pIC50 - 1
pIC50 7.3 (IC50 5.3x10-8 M) [1]
Description: Using a Transcreener FP technology assay.